Marrow Launches With 173 Million for Marrow Delivery

Marrow Therapeutics launched with $53 million Series A and $120 million Series B capital. The new Series B was led by OrbiMed. Its preclinical TAB platform aims to deliver payloads through transferrin receptor 1…




